Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 15, 2018. The report discloses the granting of conditional share awards to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline 2017 Performance Share Plan. The awards were granted on February 14, 2018, and cover a performance period of three financial years from January 1, 2018, to December 31, 2020.
Key Financial Metrics and Plan Details
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it details the financial targets and valuation metrics used for executive compensation:
- Share Price at Grant: Ordinary Shares were valued at £12.91; American Depositary Shares (ADS) were valued at $36.46.
- Performance Measures: Awards are equally weighted (1/3 each) across Total Shareholder Return (TSR), Adjusted Free Cash Flow (AFCF), and R&D New Product performance.
- AFCF Targets:
- Threshold: £11.72 billion (25% vesting)
- Mid-point: £12.08 billion (50% vesting)
- Stretch: £13.29 billion (75% vesting)
- Maximum: £13.89 billion (100% vesting)
- TSR Comparator Group: GSK is compared against AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche Holdings, and Sanofi.
Material Changes and Transactions
The filing reports the initial notification of conditional awards granted to 12 senior executives on February 14, 2018. No material changes to prior financial periods are reported as this is a disclosure of equity compensation grants rather than a financial results report.
Notable Transaction Volumes:
- Ms E Walmsley (CEO): 437,997 Ordinary Shares.
- Dr H Barron (CSO): 233,132 ADSs.
- Mr S Dingemans (CFO): 239,442 Ordinary Shares.
- Mr L Miels (President, Global Pharmaceuticals): 225,561 Ordinary Shares.
Guidance, Risks, and Unusual Items
Performance Conditions:
- TSR: 0% vests if GSK ranks 6th or lower in the comparator group. 44% vests if ranked 5th (above median). Maximum vesting occurs if ranked 1st, 2nd, or 3rd.
- R&D New Product: Specific targets are not disclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 122% of the threshold. No vesting occurs below the threshold.
- Clawback/Forfeiture: Unvested awards lapse at the end of the performance period. Executive Directors face an additional two-year vesting period (five years total), during which shares are only forfeited if terminated for cause.
Risks: The primary risk to the value of these awards is the failure to meet the specific TSR, AFCF, or R&D targets, resulting in partial or total forfeiture of the conditional shares.
Key Facts for Investor Verification
- Verify the specific R&D new product targets once disclosed at the end of the 2020 performance period, as they are currently withheld.
- Monitor GSK's TSR ranking relative to the nine specified comparator companies to assess the vesting potential of the TSR component.
- Track Adjusted Free Cash Flow performance against the £11.72bn to £13.89bn range to determine vesting percentages.
- Note that dividends accrue on the awards but only vest if the underlying shares vest.
- Confirm that the filing contains no operational financial results (revenue, earnings) for the period, serving solely as a disclosure of executive compensation grants.